论文部分内容阅读
目的:探讨5种糖皮质激素体外对淋巴系统肿瘤细胞系的相对抗肿瘤活性,并与糖皮质激素的抗炎等效剂量关系进行比较。方法:用四甲基偶氮唑盐比色法和台盼蓝计数法检测不同浓度的泼尼松、氢化可的松、泼尼松龙、甲泼尼龙和地塞米松处理淋巴系统肿瘤细胞系(U266、RPMI 8226、NCI-H929、Jurkat、和Raji)24h后的细胞半数生长抑制率和细胞半数死亡率,并计算5种激素的相对抗肿瘤活性。结果:泼尼松体外未显示抗肿瘤活性,其余4种糖皮质激素对淋巴系统肿瘤细胞系的抑制强度依次为:甲泼尼龙、泼尼松龙、地塞米松和氢化可的松,抗肿瘤等效剂量比:U266细胞7.2∶6.8∶4.2∶1.0,NCI-H929细胞6∶4∶3∶1.0,RPMI 8226细胞7.8∶6.7∶3.3∶1.0,Raji细胞5.7∶3∶1.2∶1.0,Jurkat细胞5.3∶3∶1.4∶1.0;糖皮质激素对淋巴系统肿瘤细胞系的杀伤强度与抑制强度一致,抗肿瘤等效剂量比:U266细胞2.3∶2∶1.8∶1.0,NCI-H929细胞8.8∶1.6∶1.1∶1.0,RPMI 8226细胞9.8∶1.9∶1.2∶1.0,Raji细胞17.7∶3.2∶1.9∶1.0,Jurkat细胞4.2∶1.9∶1.2∶1.0。结论:糖皮质激素的抗炎与抗淋巴系统肿瘤的等效剂量关系并不一致,这一结果值得在淋巴系统肿瘤化疗中进一步验证。
Objective: To investigate the relative anti-tumor activity of five glucocorticoids on lymphatic system tumor cell lines in vitro and to compare their anti-inflammatory equivalent dose with glucocorticoid. Methods: The lymphatic system tumor cell lines were treated with different concentrations of prednisone, hydrocortisone, prednisolone, methylprednisolone and dexamethasone by MTT colorimetry and trypan blue counting (U266, RPMI 8226, NCI-H929, Jurkat, and Raji) for half a day. The relative antitumor activities of five hormones were calculated. Results: The prednisone showed no anti-tumor activity in vitro. The inhibitory strength of the other four glucocorticoids to the lymphatic system tumor cell lines were methylprednisolone, prednisolone, dexamethasone and hydrocortisone, anti-tumor Equivalent dose ratios: U266 cells 7.2: 6.8: 4.2: 1.0, NCI-H929 cells 6: 4: 3: 1.0, RPMI 8226 cells 7.8: 6.7: 3.3: 1.0, Raji cells 5.7: 3: 1.2: 1.0, Jurkat cells 5.3: 3: 1.4: 1.0; The killing strength and inhibitory intensity of glucocorticoid on lymphatic system tumor cell lines are the same, and the antitumor equivalent dose ratio is: U266 cells 2.3: 2: 1.8: 1.0, NCI-H929 cells 8.8: 1.6: 1.1: 1.0, RPMI 8226 cells 9.8: 1.9: 1.2: 1.0, Raji cells 17.7: 3.2: 1.9: 1.0, Jurkat cells 4.2: 1.9: 1.2: 1.0. Conclusion: The relationship between the anti-inflammatory effect of glucocorticoids and the equivalent dose of anti-lymphatic system tumors is not consistent. This result is worthy of further verification in the chemotherapy of lymphatic system tumors.